Leukemia
A new model of the symptoms and impacts faced by patients may lead to better clinical tools for understanding the patient experience. Read More ›
Patients who are in a period of active observation should feel comfortable sharing anything that seems abnormal with their healthcare provider. Read More ›
A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well. Read More ›
The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect. Read More ›
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits. Read More ›
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services. Read More ›
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study. Read More ›
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered. Read More ›
Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population. Read More ›
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant. Read More ›